ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02616393
Recruitment Status : Active, not recruiting
First Posted : November 26, 2015
Last Update Posted : August 7, 2018
Sponsor:
Information provided by (Responsible Party):
Kadmon Corporation, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : October 1, 2018
  Study Completion Date : No date given